ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,355.20
0.45%
Dow Jones
44,860.31
0.28%
Brent Oil
72.215
-0.32%
Bitcoin
92,625.87
0.71%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) News

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RARE
DateTimeSourceHeadlineSymbolCompany
11/26/20244:30PMGlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in DecemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
11/20/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
11/12/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
11/09/202410:30AMGlobeNewswire Inc.Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNASDAQ:RAREUltragenyx Pharmaceutical Inc
11/05/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
11/05/20244:01PMGlobeNewswire Inc.Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/29/20244:05PMGlobeNewswire Inc.Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/18/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
10/11/20244:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/07/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/07/20248:00AMGlobeNewswire Inc.Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis ImperfectaNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/03/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/03/20244:30PMGlobeNewswire Inc.Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
09/26/20248:00AMGlobeNewswire Inc.Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
09/18/20245:00PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
09/18/20241:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
09/05/202411:50AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/29/20244:30PMGlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in SeptemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/23/20247:00AMBusiness WireTactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/21/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
08/01/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/01/20244:05PMGlobeNewswire Inc.Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/25/20244:05PMGlobeNewswire Inc.Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/24/20248:00AMGlobeNewswire Inc.Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/19/20244:05PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
07/17/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/17/20244:05PMGlobeNewswire Inc.Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/12/20244:04PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20242:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:RARE

Your Recent History

BOV
CGRA4F
GRAZZIOTIN PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21